Clear All
767 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
J1932 Lanreotide (Cipla) Lanreotide Acetate 1mg Hormonal Therapy Somatostatin Analog No 2021 Sep 27, 2022 In Use
C9430 Leuprolide Acetate Eligard, Lupron Depot, Viadur, Lupron 1 mg Hormonal Therapy GnRH Agonist No 1995 Jan 1, 2004 Jan 1, 2006 No Longer Used
Niraparib and Abiraterone Akeega Multiple Chemotherapy Androgen Receptor Inhibitor, Enzyme Inhibitor CYP 17, PARP Yes 2023 In Use
J9298 Nivolumab & Relatlimab-rmbw Opdualag 3mg/1mg Immunotherapy Checkpoint Inhibitor, Monoclonal Antibody PD-1, LAG3 No 2022 Sep 27, 2022 In Use
C9260 Ofatumumab Arzerra 10mg Immunotherapy Monoclonal Antibody CD20 No 2009 Apr 1, 2010 Dec 31, 2010 No Longer Used
J9043 Cabazitaxel Jevtana 1 mg Chemotherapy Antimitotic Agent Taxane No 2010 Jan 1, 2012 In Use
NA Cabozantinib Cabometyx 40 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2012 In Use
J2425 Palifermin Kepivance 50 mcg Ancillary Therapy Epithelial Growth Factor Keratinocyte Growth Factor/rHuKGF No 2004 Jan 1, 2006 In Use
NA Afatinib Gliotrif 40 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2013 In Use
J0594 Busulfan Busulfex 1 mg Chemotherapy Alkylating Agent Alkylsulfonate No 1999 Jan 1, 2007 In Use
J9328 Temozolomide Temodar 1 mg Chemotherapy Alkylating Agent Tetrazine No 1999 Jan 1, 2010 In Use
C9145 Aprepitant Aponvie 1mg Ancillary Therapy Antiemetic Substance P/Neurokinin 1 No 2023 Mar 17, 2023 In Use
J9047 Carfilzomib Kyprolis 1 mg Chemotherapy Proteasome Inhibitor 20S No 2012 Apr 1, 2014 In Use
Fruquintinib Fruzaqla 1mg, 5mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2023 In Use
Q0179 Ondansetron Zofran, Zofran ODT, Zuplenz 8 mg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Yes 1991 Apr 1, 1998 Dec 31, 2011 No Longer Used
J9039 Blinatumomab Blincyto 1 mcg Immunotherapy Monoclonal Antibody CD3 (T cells) and CD19 (B cells) No 2014 Jan 1, 2016 In Use
J8522 Capecitabine Multiple 50mg Chemotherapy Antimetabolite Yes 2005 Sep 11, 2024 In Use
J9352 Trabectedin Yondelis 0.1mg Chemotherapy Alkylating Agent Natural Product No 2015 Jan 1, 2017 In Use
Adagrasib Krazati 200mg Immunotherapy RAS Inhibitor KrAS G12C Yes 2022 In Use
NA Afatinib Gliotrif 20 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2013 In Use
Q2058 Obecabtagene autoleucel AUCATZYL up to 400 million Immunotherapy CAR-T CD-19 No 2024 Jul 9, 2025 In Use
J2783 Rasburicase Elitek, Fasturtec 0.5 mg Ancillary Therapy Metabolic Agent Enzyme No 2002 Jan 1, 2004 In Use
J9113 Cemiplimab-rwlc Libtayo 1mg Immunotherapy Checkpoint Inhibitor PD-1 No 2018 Oct 1, 2019 In Use
Q2050 Doxorubicin Doxil 10 mg Chemotherapy Antitumor Antibiotic Anthracycline No 1995 Jul 1, 2013 In Use
S0182 Procarbazine Matulane 50 mg Chemotherapy Alkylating Agent Benzamide Yes 1969 Jan 1, 2002 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.